Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Immunocore Holdings plcNASDAQ: IMCR
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $946.41K rose 10.8% year over year, ahead of the -22.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 53.1% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.
Context
- Depreciation & amortization amounted to 0.8% of revenue in FY2025, down 0.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10.8% holds above the trailing-twelve-month pace of -22.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
Mixed currencies · from the income statement
- Latest · FY2025
- 2.43M USD
- Year-over-year change
- -27.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.43M | -27.6% |
| FY2024 | 2024-12-31 | 3.36M | — |
| FY2023 | 2023-12-31 | 3.24M | -26.7% |
| FY2022 | 2022-12-31 | 4.41M | -21.6% |
| FY2021 | 2021-12-31 | 5.63M | — |
Depreciation & Amortization vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -22.4% is the lowest of 10, against a peer median of +0.0%.
- Depreciation & amortization amounts to 0.8% of revenue for IMCR, versus a peer median of 9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €676.85M EUR | +122.9% | +43.9% | 25.6% | |
| LTM Sep 2026 | $16.54M USD | +4.6% | -5.3% | 9.1% | |
| LTM Mar 2026 | €12.04M EUR | -2.6% | +21.9% | 32.3% | |
| LTM Jun 2026 | $10.17M USD | -10.7% | +6.1% | 9.7% | |
| LTM Jun 2026 | $10M USD | +0.0% | +18.6% | 8.5% | |
| LTM Mar 2026 | $7.09M USD | -5.1% | -15.4% | 4.5% | |
| FY2025 | €5.09M EUR | +155.3% | -51.8% | 182.7% | |
| LTM Mar 2026 | $3.14M USD | -22.4% | -18.0% | 0.8% | |
| FY2025 | A$2.13M AUD | +6.0% | +5.1% | 42.3% | |
| LTM Mar 2026 | $2.03M USD | -0.8% | +34.1% | 9.4% | |
| LTM Mar 2026 | $0 USD | — | -0.5% | 0.0% | |
| Peer median (excluding IMCR) | — | +0.0% | +5.6% | 9.5% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 27.04M | 144.23M | 197.39M | 247.98M | 297.57M |
| Cost of Revenue | 0 | 5.29M | 820.63K | 5.54M | 6.21M |
| Gross Profit | 27.04M | 138.94M | 196.57M | 242.44M | 291.36M |
| Gross Margin | 100.0% | 96.3% | 99.6% | 97.8% | 97.9% |
| Research & Development | 74.31M | 84.31M | 129.42M | 177.44M | 204.47M |
| Selling, General & Admin | 82.15M | 0 | 114.35M | 121.17M | 120.62M |
| Operating Expenses | 156.46M | 181.71M | 243.77M | 298.77M | 325.09M |
| Depreciation & Amortization | 5.63M | 4.41M | 3.24M | 3.36M | 2.43M |
| EBITDA | (123.58M) | (38.35M) | (40.87M) | (38.5M) | 387.18K |
| EBITDA Margin | -457.0% | -26.6% | -20.7% | -15.5% | 0.1% |
| Operating Income | (129.42M) | (42.77M) | (47.2M) | (56.28M) | (33.74M) |
| Operating Margin | -478.5% | -29.7% | -23.9% | -22.7% | -11.3% |
| Interest Income | 65K | 3.76M | 14.23M | 25.62M | 16.48M |
| Interest Expense | 5.57M | 5.41M | 4.08M | 18.84M | 12.17M |
| Other Income / Expenses | (3.92M) | 8.95M | (982.07K) | 14.01M | 19.53M |
| Income Before Tax | (133.34M) | (33.82M) | (48.19M) | (42.32M) | (14.21M) |
| Pre-Tax Margin | -493.0% | -23.4% | -24.4% | -17.1% | -4.8% |
| Income Tax Expense | 111.19K | 9.65M | (4.43M) | (1.48M) | 12.21M |
| Net Income | (133.45M) | (43.46M) | (43.75M) | (40.81M) | (26.42M) |
| Net Margin | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% |
| EPS (Basic) | (3.13) | (0.95) | (0.89) | (1.02) | (0.53) |
| EPS (Diluted) | (3.00) | (0.95) | (0.89) | (1.02) | (0.53) |
| Weighted Avg Shares | 42.49M | 45.71M | 48.89M | 49.99M | 50.35M |
| Weighted Avg Shares (Diluted) | 43.86M | 45.71M | 48.89M | 49.99M | 50.35M |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.